Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex.
Journal: JID innovations : skin science from molecules to population health
Published: December 22, 2022
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
Journal: ACS medicinal chemistry letters
Published: October 12, 2020
Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B.
Journal: eLife
Published: March 14, 2019
Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.
Journal: ACS medicinal chemistry letters
Published: July 30, 2015
Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Journal: Journal of medicinal chemistry
Published: September 19, 2013
Showing 1-6 of 6
Last Updated: 09/26/2026